Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 41,760 shares of Beigene stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $261.28, for a total value of $10,911,052.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Xiaodong Wang also recently made the following trade(s):
- On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The stock was sold at an average price of $254.58, for a total value of $2,073,808.68.
Beigene Stock Performance
Shares of ONC stock opened at $262.59 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a 52 week low of $126.97 and a 52 week high of $287.88. The company has a market capitalization of $25.83 billion, a price-to-earnings ratio of -31.87, a P/E/G ratio of 7.73 and a beta of 0.65.
Beigene (NASDAQ:ONC - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. On average, research analysts forecast that Beigene, Ltd. will post -5.82 EPS for the current year.
Analysts Set New Price Targets
ONC has been the subject of a number of research reports. Macquarie lifted their price target on Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Guggenheim reiterated a "buy" rating on shares of Beigene in a research note on Friday, February 28th. JMP Securities set a $348.00 price target on Beigene in a research note on Friday, February 28th. Sanford C. Bernstein set a $259.00 price target on Beigene in a research note on Thursday, March 13th. Finally, Bank of America upgraded Beigene from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd.
Check Out Our Latest Research Report on Beigene
About Beigene
(
Get Free Report)
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
